- 抑制劑
- 化合物庫
- 抗體
- 生物試劑
- 新產(chǎn)品
- 聯(lián)系我們
Home
DNA Damage/DNA Repair
DNA/RNA Synthesis inhibitor
-
COVID-19 inhibitor
-
Influenza Virus inhibitor
Favipiravir (T-705)
僅限科研使用
Favipiravir (T-705)
中文名稱：法匹拉韋
Favipiravir (T-705)是一種有效的選擇性RNA-dependent RNA polymerase抑制劑，用于治療流感病毒感染。
Favipiravir (T-705) Chemical Structure
CAS: 259793-96-9
產(chǎn)品質(zhì)控
批次：
純度：
99.97%
99.97
Favipiravir (T-705)相關產(chǎn)品
相關信號通路圖
細胞實驗數(shù)據(jù)示例
| 細胞系 | 實驗類型 | 給藥濃度 | 孵育時間 | 活性描述 | 文獻信息 |
|---|---|---|---|---|---|
| MDCK | Antiviral assay | 250 uM | 10 hrs | Antiviral activity against Influenza virus A/X-31 infected in MDCK cells assessed as inhibition of one cycle viral RNA sytheis at 250 uM added together with virus and measured at 10 hrs post infection by RT-qPCR method, NULL = NULL μM. | 29906392 |
| MDCK | Antiviral assay | 100 uM | 12 hrs | Antiviral activity against Influenza virus A/X-31 infected in MDCK cells assessed as inhibition of one cycle viral RNA synthesis at 100 uM preincubated with cells for 12 hrs followed by viral infection measured after 10 hrs post infection by RT-qPCR metho, NULL = NULL μM. | 29906392 |
| MDCK | Antiviral assay | 2 to 5 hrs | Inhibition of influenza A virus infected in MDCK cells assessed as inhibition of viral load treated with compound at 2 to 5 hrs post-infection by RT-qPCR method based time of addition assay, NULL = NULL μM. | 30192544 | |
| MDCK | Antiviral assay | 0 to 10 hrs | Inhibition of influenza A virus infected in MDCK cells assessed as inhibition of viral load treated with compound at 0 to 10 hrs post-infection by RT-qPCR method based time of addition assay, NULL = NULL μM. | 30192544 | |
| MDCK | Antiviral assay | 5 to 8 hrs | Inhibition of influenza A virus infected in MDCK cells assessed as inhibition of viral load treated with compound at 5 to 8 hrs post-infection by RT-qPCR method based time of addition assay, NULL = NULL μM. | 30192544 | |
| MDCK | Antiviral assay | 0 to 2 hrs | Inhibition of influenza A virus infected in MDCK cells assessed as inhibition of viral load treated with compound at 0 to 2 hrs post-infection by RT-qPCR method based time of addition assay, NULL = NULL μM. | 30192544 | |
| Vero | Antiviral assay | 6400 uM | up to 12 hrs | Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as time required for inhibition of viral replication at 6400 uM up to 12 hrs post-viral infection, NULL = NULL μM. | 18955536 |
| MDCK | Antiviral assay | 128 uM | Antiviral activity against adamantane-resistant,oseltamivir-susceptible Influenza A virus (A/pdm/California/04/2009(H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as determination of viral titer in cell culture at 128 uM , NULL = NULL μM. | 20350949 | |
| MDCK | Antiviral assay | 128 uM | Antiviral activity against adamantane-resistant,oseltamivir-susceptible Influenza A virus (A/pdm/Mexico/4604/2009(H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as determination of viral titer in cell culture at 128 uM af, NULL = NULL μM. | 20350949 | |
| MDCK | Antiviral assay | Antiviral activity against 0.001 MOI adamantane-resistant,oseltamivir-susceptible Influenza A virus (A/pdm/California/04/2009(H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as determination of viral titer in cell culture , NULL = NULL μM. | 20350949 | ||
| MDCK | Antiviral assay | Antiviral activity against 0.001 MOI adamantane-resistant,oseltamivir-susceptible Influenza A virus (A/pdm/Mexico/4604/2009(H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as determination of viral titer in cell culture at, NULL = NULL μM. | 20350949 | ||
| MDCK | Antiviral assay | 3 days | Antiviral activity against Influenza virus A/X-31 infected in MDCK cells assessed as reduction in viral replication at 3 days post infection by formazan-based MTS assay, EC50 = 26 μM. | 29906392 | |
| Vero-A | Antiviral assay | Antiviral activity against Chikungunya virus LR2006-OPY1 infected in African green monkey Vero-A cells assessed as inhibition of viral-induced cytopathic effect measured on day 7 post infection by MTS/PMS assay, EC50 = 25 μM. | 28689975 | ||
| Vero-A | Antiviral assay | Antiviral activity against Chikungunya virus 899 infected in African green monkey Vero-A cells assessed as inhibition of viral-induced cytopathic effect measured on day 7 post infection by MTS/PMS assay, EC50 = 25 μM. | 28689975 | ||
| MDCK | Antiviral assay | 3 days | Antiviral activity against Influenza virus A/X-31 infected in MDCK cells assessed as reduction in viral replication at 3 days post infection by microscopic analysis, EC50 = 24 μM. | 29906392 | |
| MDCK | Antiviral assay | Antiviral activity against oseltamivir-susceptible, adamantane-resistant Influenza A virus (A/pdm/Illinois/10/2009(H1N1)) harboring M2 V28I, S31N mutant and neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral repli, EC50 = 22.48 μM. | 20350949 | ||
| Vero-A | Antiviral assay | Antiviral activity against Chikungunya virus venturini isolate (Italy 2008) infected in African green monkey Vero-A cells assessed as inhibition of viral-induced cytopathic effect measured on day 7 post infection by MTS/PMS assay, EC50 = 16 μM. | 28689975 | ||
| MDCK | Antiviral assay | Inhibition of Influenza A virus (A/gull/Pennsylvania/4175/83 (H5N1)) replication in MDCK cells by neutral red uptake assay, EC50 = 11.5 μM. | 17194832 | ||
| MDCK | Antiviral assay | Inhibition of viral replication of influenza A virus (A/Vietnam/1203/2004 (H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay, EC50 = 12.1 μM. | 17194832 | ||
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-resistant,Influenza A virus (A/New York/107/2003(H7N2)) harboring M2 V28A, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic , EC50 = 10.2 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against Influenza virus B/Ned/537/05 infected in MDCK cells assessed as reduction in viral replication at 3 days post infection by microscopic analysis, EC50 = 9 μM. | 29906392 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against Influenza virus B/Ned/537/05 infected in MDCK cells assessed as reduction in viral replication at 3 days post infection by formazan-based MTS assay, EC50 = 8.3 μM. | 29906392 | |
| MDCK | Antiviral assay | Inhibition of Influenza A virus (A/gull/Pennsylvania/4175/83 (H5N1)) replication in MDCK cells by virus yield reduction assay, EC90 = 7.7 μM. | 17194832 | ||
| MDCK | Antiviral assay | 1 hr | 3 days | Antiviral activity against Influenza A virus (A/Taiwan/1/1986(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis, EC50 = 6.95 μM. | 23419738 |
| MDCK | Antiviral assay | Antiviral activity against, adamantane-resistant Influenza A virus (A/pdm/Washington/29/2009 (H1N1)) harboring M2 V28I, S31N mutant and neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral re, EC50 = 6.62 μM. | 20350949 | ||
| Vero | Antiviral assay | 7 to 8 days | Antiviral activity against Pichinde virus An 4763 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days, EC50 = 6 μM. | 17606691 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-resistant, Influenza A virus (A/Wuhan/395/1995-like (H3N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal viole, EC50 = 5.99 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against, adamantane-resistant Influenza A virus (A/Wuhan/395/1995-like (H3N2)) harboring neuraminidase E119V mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by mi, EC50 = 5.41 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-resistant Influenza B virus (B/New York/22/2008) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 5.3 μM. | 20350949 | |
| MDCK | Antiviral assay | Antiviral activity agains, adamantane-resistant Influenza A virus (A/Texas/12/2007 (clone)(H3N2)) harboring neuraminidase E119V mutant and harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral , EC50 = 5.22 μM. | 20350949 | ||
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-resistant,Influenza A virus (A/Vietnam/1203/2004 clade 1 (H5N1)) harboring M2 L26I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by mic, EC50 = 5.22 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against, adamantane-resistant Influenza B virus (B/Michigan/20/2005) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic , EC50 = 5.03 μM. | 20350949 | |
| Vero | Antiviral assay | 7 to 8 days | Antiviral activity against Junin virus Candid-1 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days, EC50 = 5 μM. | 17606691 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-,Influenza A virus (A/New Jersey/15/2007(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micr, EC50 = 4.9 μM. | 20350949 | |
| MDCK | Antiviral assay | 1 hr | Antiviral activity against Influenza A virus (A/Hong kong/8/1968(H2N3)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis, EC50 = 4.71 μM. | 23419738 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-susceptible,Influenza A virus (A/Santiago/5248/2008(H1N1)) harboring neuraminidase D198E mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micr, EC50 = 4.7 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-,Influenza A virus (A/Swine/Texas/14/2008 (H1N1)) harboring M2 V27T, V28D mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic anal, EC50 = 4.52 μM. | 20350949 | |
| MDCK | Antiviral assay | Inhibition of influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) replication in MDCK cells by neutral red uptake assay, EC50 = 4.5 μM. | 17194832 | ||
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-resistant,Influenza A virus (A/Washington/01/2007(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analy, EC50 = 4.46 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-resistant,Influenza A virus (A/Massachusetts/03/2009(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic an, EC50 = 4.2 μM. | 20350949 | |
| MDCK | Antiviral assay | Antiviral activity against, adamantane-resistant Influenza A virus (A/Vietnam/HN30408/2005 H274Y clade 1 (H5N1)) harboring M2 L26I, S31N mutant and neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition, EC50 = 4.14 μM. | 20350949 | ||
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-resistant,Influenza A virus (A/New Hampshire/01/2009(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic an, EC50 = 4.08 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-resistant, Influenza B virus (B/Illinois/47/2005) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 4.01 μM. | 20350949 | |
| MDCK | Antiviral assay | Antiviral activity against, adamantane-resistant Influenza A virus (A/Texas/12/2007 (clone)(H3N2)) harboring neuraminidase E119I mutant and harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral , EC50 = 3.95 μM. | 20350949 | ||
| MDCK | Antiviral assay | Inhibition of viral replication of influenza A virus (A/Vietnam/1203/2004 (H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by virus yield reduction assay, EC90 = 3.8 μM. | 17194832 | ||
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-,Influenza A virus (A/California/27/2007(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 3.63 μM. | 20350949 | |
| MDCK | Antiviral assay | Antiviral activity against adamantane-susceptible , Influenza A virus (A/duck/Vietnam/NCVD94/2007 clade 2.3.4 (H5N1)) harboring neuraminidase I117V mutant infected in MDCK cells assessed as inhibition of viral replication a, EC50 = 3.38 μM. | 20350949 | ||
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-,Influenza B virus (B/Illinois/03/2008) harboring neuraminidase E119A mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis u, EC50 = 3 μM. | 20350949 | |
| MDCK | Antiviral assay | Antiviral activity against, adamantane-resistant Influenza A virus (A/Luhansk/18/2008(H1N1)) harboring neuraminidase H274Y mutant and M2 G34E mutant infected in MDCK cells assessed as inhibition of viral replication afte, EC50 = 2.93 μM. | 20350949 | ||
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-, Influenza A virus (A/Idaho/01/2009(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysi, EC50 = 2.93 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-resistant,Influenza A virus (A/Wisconsin/16/2008(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros, EC50 = 2.87 μM. | 20350949 | |
| MDCK | Antiviral assay | 1 hr | Antiviral activity against Influenza B virus (B/Taiwan/2/62) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis, EC50 = 2.84 μM. | 23419738 | |
| MDCK | Antiviral assay | 24 hrs | Antiviral activity against Influenza A virus A/WSN/33(H1N1) infected in MDCK cells assessed as inhibition of neuraminidase activity using 2'-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid substrate pretreated with cells for 24 hrs followed by vira, EC50 = 2.7 μM. | 27120583 | |
| MDCK | Antiviral assay | Inhibition of influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) replication in MDCK cells by virus yield reduction assay, EC90 = 2.6 μM. | 17194832 | ||
| MDCK | Antiviral assay | Inhibition of viral replication of influenza A virus (A/Hong Kong/213/03(H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay, EC50 = 2.6 μM. | 17194832 | ||
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-,Influenza A virus (A/swine/Michigan/09/2007 (H1N2)) harboring M2 V27I, V28D mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic a, EC50 = 2.23 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-resistant，Influenza A virus (A/pdm/California/04/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros, EC50 = 1.97 μM. | 20350949 | |
| MDCK | Antiviral assay | 1 hr | Antiviral activity against Influenza B virus (B/Panama/45/1990) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis, EC50 = 1.94 μM. | 23419738 | |
| MDCK | Antiviral assay | 1 hr | Antiviral activity against Influenza B virus (B/Lee/40) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis, EC50 = 1.93 μM. | 23419738 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-, Influenza A virus (A/Brazil/1067/2008(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 1.85 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against, adamantane-resistant Influenza B virus (B/Rochester/01/2001) harboring neuraminidase D198N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic, EC50 = 1.72 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-，Influenza A virus (A/duck/Vietnam/NCVD93/2007 clade 2.3.4 (H5N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using cry, EC50 = 1.59 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-,Influenza A virus (A/Florida/21/2008(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microsc, EC50 = 1.59 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-,Influenza A virus (A/turkey/VA/4529/2002 (H7N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 1.53 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-， Influenza A virus (A/Georgia/17/2006(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 1.46 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-resistant,Influenza B virus (B/Rochester/01/2001) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 1.4 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-resistant,Influenza A virus (A/pdm/California/07/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros, EC50 = 1.4 μM. | 20350949 | |
| MDCK | Antiviral assay | Antiviral activity against adamantane-, Influenza A virus (A/Vietnam/HN30408/2005 N294S clade 1 (H5N1)) harboring M2 L26I, S31N mutant and neuraminidase N294S mutant infected in MDCK cells assessed as inhibition of viral , EC50 = 1.341 μM. | 20350949 | ||
| MDCK | Antiviral assay | 1 hr | Antiviral activity against Influenza B virus (B/Brisbane/60/2008) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis, EC50 = 1.32 μM. | 23419738 | |
| MDCK | Antiviral assay | Inhibition of viral replication of influenza A virus (A/Hong Kong/213/03(H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by virus yield reduction assay, EC90 = 1.3 μM. | 17194832 | ||
| MDCK | Antiviral assay | Antiviral activity against adamantane，Influenza A virus (A/chicken/Vietnam/NCVD103/2007 clade 2.3.4 (H5N1)) harboring neuraminidase I222T mutant infected in MDCK cells assessed as inhibition of viral replication after, EC50 = 1.27 μM. | 20350949 | ||
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-resistant,Influenza B virus B/Memphis/20/1996 infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 1.21 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-resistant ,Influenza A virus (A/pdm/Mexico/4604/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microsco, EC50 = 1.21 μM. | 20350949 | |
| MDCK | Antiviral assay | Antiviral activity against, adamantane-resistant Influenza A virus (A/Bethesda/956/2006(H3N2)) harboring neuraminidase R292K mutant and M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication af, EC50 = 1.21 μM. | 20350949 | ||
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-, Influenza A virus (A/turkey/Minnesota/833/1980(H4N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet , EC50 = 0.96 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-, Influenza A virus (A/turkey/Minnesota/833/1980(H4N2)) harboring neuraminidase E119G mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days , EC50 = 0.89 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-resistant,Influenza A virus (A/pdm/New York/18/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microsco, EC50 = 0.89 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-resistant,Influenza A virus (A/pdm/California/05/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros, EC50 = 0.83 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-susceptible ,Influenza A virus (A/Brazil/1633/2008(H1N1)) harboring neuraminidase Q136K mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros, EC50 = 0.83 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against, adamantane-resistant Influenza B virus B/Memphis/20/1996 harboring neuraminidase R152K mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic ana, EC50 = 0.57 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-resistant,Influenza A virus (A/Florida/01/2009(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis, EC50 = 0.45 μM. | 20350949 | |
| MDCK | Antiviral assay | 10 uM | up to 8 hrs | Antiviral activity against Influenza A virus (A/chicken/Hubei/327/2004(H5N1)) infected in MDCK cells assessed as inhibition of early stages of viral replication at 10 uM up to 8 hrs by crystal violet staining based plaque reduction assay dependent time-of, NULL = NULL μM. | 30292897 |
| Vero | Antiviral assay | 7 to 8 days | Antiviral activity against Tacaribe virus TRVL11573 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days, EC50 = 6 μM. | 17606691 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-,Influenza A virus (A/North Carolina/02/ 2009(H1N1)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic, EC50 = 5.03 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-,Influenza A virus (A/Washington/10/2008(H1N1)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic anal, EC50 = 3.25 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-,Influenza A virus (A/Georgia/20/2006(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microsc, EC50 = 2.55 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-,Influenza A virus (A/Ecuador/5179/2008(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 2.48 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-， Influenza A virus (A/Swine/South Dakota/03/2008(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet, EC50 = 0.83 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-resistant , Influenza A virus (A/New York/34/2008(H1N1)) harboring M2 L26I mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysi, EC50 = 0.19 μM. | 20350949 | |
| MDCK | Antiviral assay | 3 days | Antiviral activity against adamantane-, Influenza A virus (A/Ann Arbor/6/1960(H2N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 0.38 μM. | 20350949 | |
| 點擊查看更多細胞系數(shù)據(jù) | |||||
生物活性
| 產(chǎn)品描述 | Favipiravir (T-705)是一種有效的選擇性RNA-dependent RNA polymerase抑制劑，用于治療流感病毒感染。 | |
|---|---|---|
| 靶點 |
|
| 體外研究(In Vitro) | ||||
| 體外研究活性 | Favipiravir表現(xiàn)出抗流感病毒活性，對甲型流感病毒，乙型流感病毒和丙型流感病毒的IC50 范圍分別為0.013-0.48 μg/ml，0.039-0.089 μg/ml，和0.030-0.057 μg/ml。在哺乳動物細胞系 (MDCK細胞，Vero細胞，HEL細胞，A549細胞，HeLa細胞，和HEp-2 細胞) 中，高達1,000 μg/ml 濃度的Favipiravir沒有表現(xiàn)出毒性。[1]在接種季節(jié)性甲型流感(H1N1)病毒的MDCK細胞中，F(xiàn)avipiravir誘導致死性突變發(fā)生。[2] | |||
|---|---|---|---|---|
| 細胞實驗 | 細胞系 | MDCK細胞，Vero細胞，HEL細胞，A549細胞，HeLa細胞，和 HEp-2 細胞 | ||
| 濃度 | 1000 μg/mL | |||
| 孵育時間 | 3天 | |||
| 方法 | T-705的毒性通過XTT試驗評估。在MDCK細胞，Vero細胞，HEL 細胞，A549細胞，HeLa 細胞，和HEp-2細胞中，XTT通過酶轉(zhuǎn)化為含水的甲臜?；衔镉脺y試培養(yǎng)基(包含10% FCS的EMEM)在96孔板中(2 × 103細胞/100 μL)稀釋為適當?shù)臐舛?體積，100 μl)。測試板在37°C，100% 濕度和5% CO2中培育3天。3天后，加入50 μl XTT試劑(在包含5 mM吩嗪硫酸甲酯的無FCS的EMEM中濃度為1 mg/ml)，反應產(chǎn)物使用酶標儀測量450 nm下的吸光度測定。細胞毒性表示為50% 細胞抑制濃度(CC50)。 | |||
| 實驗圖片 | 檢測方法 | 檢測指標 | 實驗圖片 | PMID |
| Growth inhibition assay | Survival Cell viability |
|
26711718 | |
| IHC | H&E Staining NiV nucleoprotein LASV antigen H&E stain |
|
29765101 | |
| Immunofluorescence | rNiV-Gluc |
|
29765101 | |
| 體內(nèi)研究(In Vivo) | ||
| 體內(nèi)研究活性 | 在流感病毒感染的小鼠中，F(xiàn)avipiravir (200 mg/kg/day, p.o.)保護小鼠不被流感病毒感染而死亡。[1]在人工感染Ebola病毒的小鼠中，F(xiàn)avipiravir有效阻斷病毒產(chǎn)生，在治療起始2天和6天后分別達到95%和99.6%的抗病毒效果。[3] | |
|---|---|---|
| 動物實驗 | Animal Models | 感染流感病毒 A/PR/8/34的小鼠 |
| Dosages | 200 mg/kg/day | |
| Administration | p.o. | |
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06024421 | Recruiting | Infectious Disease|Pharmacology |
Institut National de la Santé Et de la Recherche Médicale France|FUJIFILM Toyama Chemical Co. Ltd. |
April 2024 | Phase 1 |
| NCT05940545 | Recruiting | CCHF |
Liverpool School of Tropical Medicine |
July 12 2023 | Phase 1|Phase 2 |
| NCT04907682 | Completed | Lassa Fever |
Bernhard Nocht Institute for Tropical Medicine|University of Hamburg-Eppendorf|Alliance for International Medical Action|Institut National de la Santé Et de la Recherche Médicale France|University of Bordeaux|Federal Medical Centre Owo|Irrua Specialist Teaching Hospital |
July 30 2021 | Phase 2 |
化學信息&溶解度
| 分子量 | 157.1 | 分子式 | C5H4FN3O2 |
| CAS號 | 259793-96-9 | SDF | Download Favipiravir (T-705) SDF |
| Smiles | C1=C(N=C(C(=O)N1)C(=O)N)F | ||
| 儲存條件(自收到貨起) | |||
|
體外溶解度 |
DMSO : 31 mg/mL ( (197.32 mM) ；DMSO吸濕會降低化合物溶解度，請使用新開封DMSO) Water : 2 mg/mL (12.73 mM) Ethanol : 2 mg/mL (12.73 mM) |
摩爾濃度計算器 |
|
體內(nèi)溶解度 現(xiàn)配現(xiàn)用，請按從左到右的順序依次添加，澄清后再加入下一溶劑 |
動物體內(nèi)配方計算器 | ||||
實驗計算
動物體內(nèi)配方計算器（澄清溶液）
第一步：請輸入基本實驗信息（考慮到實驗過程中的損耗，建議多配一只動物的藥量）
mg/kg
g
μL
只
第二步：請輸入動物體內(nèi)配方組成（配方適用于不溶于水的藥物；不同批次藥物配方比例不同，請聯(lián)系Selleck為您提供正確的澄清溶液配方）
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
計算結(jié)果：
工作液濃度： mg/ml；
DMSO母液配制方法： mg 藥物溶于μL DMSO溶液（母液濃度mg/mL，注：如該濃度超過該批次藥物DMSO溶解度，請先聯(lián)系Selleck）；
體內(nèi)配方配制方法：取μL DMSO母液，加入μL PEG300，混勻澄清后加入μL Tween 80，混勻澄清后加入μL ddH2O，混勻澄清。
體內(nèi)配方配制方法：取μL DMSO母液，加入μL Corn oil，混勻澄清。
注意：1. 首先保證母液是澄清的；
2.一定要按照順序依次將溶劑加入，進行下一步操作之前必須保證上一步操作得到的是澄清的溶液，可采用渦旋、超聲或水浴加熱等物理方法助溶。
技術(shù)支持
在訂購、運輸、儲存和使用我們的產(chǎn)品的任何階段，您遇到的任何問題，均可以通過撥打我們的熱線電話400-668-6834，或者技術(shù)支持郵箱tech@selleck.cn，直接聯(lián)系到我們。我們會在24小時內(nèi)盡快聯(lián)系您。
如果有其他問題，請給我們留言。
* 必填項
Tags: buy Favipiravir (T-705) | Favipiravir (T-705) supplier | purchase Favipiravir (T-705) | Favipiravir (T-705) cost | Favipiravir (T-705) manufacturer | order Favipiravir (T-705) | Favipiravir (T-705) distributor
